PMID: 7526227Jul 1, 1994Paper

Pretreatment with interleukin-1 enhances survival of sympathetic ganglionic neuron grafts

Neurologia Medico-chirurgica
N NakaoS Furukawa

Abstract

The effects of pretreatment with interleukin-1 (IL-1) on neurite growth and cell survival of rat superior cervical ganglion (SCG) explants were examined. Neonate rat SCG explants were cultured with serum-containing growth media. Pretreatment with IL-1 beta (30 U/ml) for 3 hours stimulated neurite outgrowth of the SCG explant, which was inhibited by the addition of anti-nerve growth factor (NGF) antibody to the growth medium. Adult rat autologous SCG with the same pretreatment and non-treated ganglia were transplanted into the lateral ventricle. Histological evaluation of the grafts 2 weeks after transplantation revealed that the pretreated SCG cells survived better. Pretreatment with IL-1 may achieve the NGF-mediated neurotrophic effect in sympathetic ganglionic neurons resulting in enhanced graft survival.

Citations

Jun 1, 2005·Brain Research. Molecular Brain Research·Guillaume HébertJacques Demotes-Mainard
Jan 10, 2002·Journal of Neuroscience Research·Karin Edoff, Helena Jerregård
May 12, 2016·Reviews in the Neurosciences·Amene SaghazadehNima Rezaei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.